

CHEMISTRY OF TRUST



History

1985

Inception

1989

Expansion

1995

IPO & Listing
of Vikram

1997

Started
DRUGCOAT

2006

New cGMP - compliant
manufacturing facility.

2014

India's First
EXCiPACT Certified
Company

Credentials

Company has state of the art manufacturing facility certified with International EXCiPACT GMP certificate. A combine certificate of IPEC EUROPE and IPEC USA for manufacturing international standard pharma Polymers (EXCIPIENTS). EXCiPACT, Good Manufacturing Practice, ISO 9001:2008 and Halal certificate and many multinational company audit approval enabling pharmacopeial GMP International quality product manufacturing in India. Vikram Thermo (India) Limited filed US-DMF approvals across its product range.



DRUGCOAT® Polymers

DRUGCOAT® has played a pivotal role in the evolution of the global pharmaceutical industry, setting new benchmarks in oral drug delivery. DRUGCOAT® presence accelerated the industry's transition from conventional coatings to scientifically engineered polymers, enabling modified-release, targeted-delivery, and stability-enhancing dosage forms.





2018

Became Asia's largest manufacturing capacity.

2022

New flagship product launch

2025

Launched advanced R&D initiatives

Mission

Our mission is to be a global leader in excipients, driven by advancement, reliability & expertise. Delivering international quality, cost-effective solutions every time.

Vision

To create excipients that improve lives, safeguard the planet, & leave a lasting impact on communities & industries worldwide.

“Accelerating the future of oral drug delivery.”

By bridging gaps between pharmaceutical science, industrial scalability, and regulatory compliance, DRUGCOAT® has become a cornerstone technology, elevating industry standards, driving innovation, and redefining the potential of modern drug development.





DRUGCOAT® L&S Series

Targeted drug delivery with
precise pH-controlled release

Advantages:

Reliable gastro-resistance

pH-controlled dissolution
and release

Accurate gastrointestinal
targeting

Protection of acid-labile
active ingredients

Safeguarding gastric
mucosa from irritant
drugs

Optimized drug
bioavailability and
therapeutic effectiveness

Excellent film stability and
storage robustness

Protecting oral therapies from the stomach's harsh acidic environment, DRUGCOAT® L and S series polymers offer reliable gastro-resistance and controlled intestinal targeting. Developed using advanced polymerization, these polymers dissolve only above defined pH thresholds ensuring drug release occurs at the intended absorption site.

By selecting the appropriate grade, formulators can fine-tune dissolution onset with high precision, accurately targeting specific regions of the gastrointestinal tract, including the colon. This makes DRUGCOAT® L & S series especially valuable for therapies addressing intestinal disorders.

Curing: Essential for film formation and stability.

Curing is a critical post-coating step for enteric films using methacrylic acid polymers, ensuring a uniform, stable, and functional coating that dissolves at the intended intestinal pH.

Process: Coated tablets or pellets are cured at 40–50°C for 30–45 minutes under low relative humidity (<30–40%) to promote polymer coalescence, improve adhesion, and prevent defects such as cracking or dose dumping.

Benefits of curing

- Ensures film integrity
- Improves acid resistance
- Stabilizes performance
- Reduces variability
- Prevents dose dumping
- Enhances mechanical strength



**Adapted the advance
technology in 1995**

**Ahead in time always, we started the
advanced DRUGCOAT® L&S series in
1995, and adapted the aqueous
polymerization technology.**

DRUGCOAT® L&S SERIES

DRUGCOAT® Series	Physical Form	Monograph	Dissolution Properties
AQUEOUS ENTERIC COATING			
DRUGCOAT® L 30D	Aqueous Dispersion 30%	USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer Dispersion Ph. Eur.: Methacrylic Acid-Ethyl Acrylate Copolymer(1:1) Dispersion 30%	Dissolve above pH 5.5
DRUGCOAT® L 100-55	Powder	USP/NF: Methacrylic Acid And Ethyl Acrylate Copolymer Ph. Eur.: Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Type A	
DRUGCOAT® L 100-55D	Powder	USP/NF: Partially-Neutralized Methacrylic Acid & Ethyl Acrylate Copolymer Ph. Eur.: Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Type B	
NON AQUEOUS ENTERIC COATING			
DRUGCOAT® L 100	Powder	USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:1) Ph. Eur.: Methacrylic Acid–Methyl Methacrylate Copolymer (1:1)	Dissolve above pH 6.0
DRUGCOAT® L 12.5	Organic Solution 12.5%		
COLON TARGETED ENTERIC COATING			
DRUGCOAT® S 100	Powder	USP/NF: Methacrylic Acid And Methyl Methacrylate Copolymer (1:2) Ph. Eur.: Methacrylic Acid–Methyl Methacrylate Copolymer (1:2)	Dissolve above pH 7.0
DRUGCOAT® S 12.5	Organic Solution 12.5%		
DRUGCOAT® FS 30D	Aqueous Dispersion 30%	USP/NF : Methyl Acrylate, Methyl Methacrylate and Methacrylic Acid (7:3:1) Copolymer Dispersion	



DRUGCOAT® E Series

Protect, mask and enhance

Advantages:

pH- dependent drug release

Moisture protection

Improves patient compliance

Protection of API from environmental factors

Taste and odour masking

Improves storage stability of sensitive APIs

Lowest WVTR in its class

DRUGCOAT® E series polymers provide a complete solution for moisture-sensitive actives, while improving patient acceptability through effective taste and odor masking. Their smooth, glossy coatings make tablets and capsules easier to swallow, visually appealing, and easy to identify.

Despite their effectiveness, the desired functionality can be achieved with an ultra-thin coating, offering a highly efficient and cost-effective approach for immediate release formulations. Built on advanced cationic polymer technology, DRUGCOAT® E series polymers offer superior resistance to ambient moisture compared to conventional hydrocolloid systems, ensuring effective protection of the active ingredient throughout its shelf life. Additional advantages include high adhesion to substrates, excellent pigment load capacity, and smooth, efficient application.

Engineered to protect, simplify administration, and optimize production, DRUGCOAT® E series supports both pharmaceutical performance and patient satisfaction.

Solubility and drug loading - Itraconazole

DRUGCOAT® EPO Multifunctional polymer for itraconazole pellets

DRUGCOAT® EPO is a cationic copolymer widely used in itraconazole pellet formulations to address the drug's poor water solubility and bitter taste.

It serves multiple functions: Taste masking by forming a protective film that prevents drug release in the mouth, and solubility enhancement by maintaining itraconazole in an amorphous, high-energy state through solid dispersions. DRUGCOAT® EPO being pH-sensitive it dissolves in gastric fluids below pH 5.0.

This enables rapid drug release in the stomach, where itraconazole is most soluble and readily absorbed, improving oral bioavailability.

It also stabilizes amorphous form of itraconazole, preventing recrystallization and ensuring consistent drug performance. Overall, DRUGCOAT® EPO enhances taste, solubility, release profile, and bioavailability, making it a critical polymer for high-performance itraconazole pellet formulations.

DRUGCOAT® E SERIES

DRUGCOAT® Series	Physical Form	Monograph	Dissolution Properties
DRUGCOAT® E 100	Granules	USP/NF: Amino Methacrylate Copolymer Ph. Eur.: Basic Butylated Methacrylate Copolymer	Dissolve upto pH 5.0 Soluble in gastric fluid
DRUGCOAT® E PO	Powder		
DRUGCOAT® E 12.5	Organic Solution 12.5%		



Advance moisture protection

Since 20th century we developed the advanced moisture protection DRUGCOAT®E series which provides advanced moisture protection, forming a tight shield that prevents moisture ingress and preserves drug stability.



Always ahead in technology

Since the 19th century, we've led the way with solution polymerization technology, laying the groundwork for today's advanced manufacturing excellence in industry.

DRUGCOAT® RL, RS & NE Series

Flexible solutions for customized drug release

Achieve precise and predictable drug release with the flexible DRUGCOAT® RL, RS & NE series - adaptable across various drug delivery applications. Whether you're aiming multiparticulate or matrix formulations, these polymers allow you to control precise release profile you want. Regulate the drug's journey through the gastrointestinal tract, boosting therapeutic effectiveness and easy patient adherence.

By combining polymers from the DRUGCOAT® RL and RS grades with other excipients, formulators can develop tailor-made formulations that deliver the active ingredient exactly as intended, ensuring predictable performance and reliable clinical outcomes.

Advantages:

For sustain release
of API

Customized release
profiles

Prolongation of effective
plasma level

Reduction of total dose

Reduce risk of dose
dumping

Reduce toxicological
effect of APIs

Reduction of dose
frequency


Increase patient
compliance

Customizable release kinetics

DRUGCOAT® RL 100 & RS 100

Different ratios of DRUGCOAT® RL 100 and RS 100 can be employed to enable precise fine tuning of drug release profiles in sustained release formulations. RL 100, with higher permeability, allows faster water penetration and initial drug diffusion, while RS 100, being less permeable, slows polymer erosion to extend release.

By adjusting their relative ratios, formulators can achieve an optimal balance between diffusion and retardation, providing customizable release kinetics tailored to match the therapeutic requirements. This flexibility makes RL - RS blends a highly valuable tool for designing sustained-release oral dosage forms with a predictable, controlled performance.



DRUGCOAT® RL, RS & NE SERIES

DRUGCOAT® Series	Physical Form	Monograph	Dissolution properties
DRUGCOAT® RL 100	Granules	USP/NF: Ammonio Methacrylate Copolymer, Type A PPh. Eur.: Ammonio Methacrylate Copolymer, Type A	pH-independent swelling
DRUGCOAT® RL PO	Powder		
DRUGCOAT® RL 12.5	Organic Solution 12.5%		
DRUGCOAT® RS 100	Granules	USP/NF: Ammonio Methacrylate Copolymer, Type B PPh. Eur.: Ammonio Methacrylate Copolymer, Type B	
DRUGCOAT® RS PO	Powder		
DRUGCOAT® RS 12.5	Organic Solution 12.5%		
DRUGCOAT® NE 30D	Aqueous Dispersion 30%	USP/NF: Ethyl Acrylate And Methyl Methacrylate Copolymer Dispersion Ph. Eur.: Polyacrylate Dispersion 30%	

Targeted drug release with DRUGCOAT®

Enteric formulations

Duodenum pH > 5.5

DRUGCOAT® L 30D
DRUGCOAT® L 100-55
DRUGCOAT® L 100-55D

Jejunum pH 6-7

DRUGCOAT® L 100
DRUGCOAT® L 12.5

Colon pH > 7

DRUGCOAT® S 100
DRUGCOAT® S 12.5
DRUGCOAT® FS 30D

Protective formulations

Stomach


DRUGCOAT® E 100
DRUGCOAT® E 12.5
DRUGCOAT® E PO

Sustained - release formulations

Time controlled
release

pH
independent

DRUGCOAT® RL 100
DRUGCOAT® RL PO
DRUGCOAT® RL 12.5
DRUGCOAT® RS 100
DRUGCOAT® RS PO
DRUGCOAT® RS 12.5
DRUGCOAT® NE 30D



The Vikram Thermo Impact

"Vikram's advance coating technology improved patient adherence which directly translated into accelerated business growth."

- CEO of a Multinational Pharma Company.

Impact on your business

Regulatory confidence by simplified documentation and compliance for approvals and exports.

Predictable supply ensures consistent inventory, reducing emergency sourcing and production delays.

Faster time-to-market by reducing formulation iterations and shortens development cycles.

Lower risk and fewer rejects by minimizing batch failures.

Improved product stability extending shelf life and reduces degradation issues.

Higher patient acceptance by enhancing taste-masking and appearance to improve adherence.

How we deliver value

R&D partnership provides formulation trials and scale-up support in our labs.

Technical service offers on-site trials, process optimization, and tech transfer assistance.

Product range includes ready-to-use systems and custom polymer solutions.

Regulatory pack covers COAs, stability protocols, DMF support, and regulatory documentation.

Reliable manufacturing ensures EXCiPACT GMP, ISO, and HALAL certifications with consistent quality.



Real world result



Increased manufacturing yield



Reduced rework and rejection



Increased savings on cost



Decreased development time

How we can help you next

○ **Sample & compatibility testing:** We'll run tests & provide a detailed report.

○ **ROI projection:** Model savings from switching coatings (yield, time, rejects).

○ **Regulatory support:** Prepare complete documentation for export approvals.



Excellence in Pharma Polymer

The information provided herein, along with any related technical guidance or recommendations, is based on Vikram Thermo (India) Limited's current knowledge, research, and experience. While every effort is made to ensure accuracy, Vikram Thermo assumes no responsibility or liability for the completeness or suitability of such information for specific applications. Vikram Thermo reserves the right to modify, update, or withdraw any information or technical advice without prior notice. No representations or warranties, express or implied, are made regarding the merchantability or fitness of the product for a particular purpose.

Under no circumstances shall Vikram Thermo (India) Limited be held liable for any direct, indirect, incidental, or consequential damages (including, without limitation, loss of profits) arising from the use of this information or the products described. It is the user's responsibility to verify the suitability and performance of all products through their own testing and evaluation by qualified professionals. Any references to third-party trade names are provided solely for identification and do not constitute endorsement or imply that equivalent products cannot be used.



Vikram Thermo (India) Limited,

Regd. Office

A/704 - 714, The Capital, Science City Rd,

Ahmedabad - 380060, Gujarat, India.

+91-79-48481010/11/12

www.vikramthermo.com

contact@vikramthermo.com

CIN No: L24296GJ1994PLC021524

CHEMISTRY OF TRUST